Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.xcrm.2021.100218 http://scihub22266oqcxt.onion/10.1016/j.xcrm.2021.100218 33649747!7904445!33649747     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Rep+Med 2021 ; 2 (3): 100218 Nephropedia Template TP {{tp|p=33649747|t=2021. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters |pdf=|usr=}}{{33649747}} gab.com Text Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters JO: Cell Rep Med http://www.kidney.de/pget.php?&tw=1&pmid=33649747 #FOAvip SARS-CoV-2 infection results in viral burden in the respiratory tract, enabling transmission and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody was derived from an IgM memory B cell of a COVID-19 patient, has high affinity for the Spike protein receptor binding domain, neutralizes SARS-CoV-2, and exhibits in vivo prophylactic and therapeutic activity in hamsters when delivered intraperitoneally, reducing upper and lower respiratory viral burden and lung pathology. Inhalation of nebulized 1212C2 at levels as low as 0.6 mg/kg, corresponding to 0.03 mg/kg lung-deposited dose, reduced the viral burden below the detection limit and mitigated lung pathology. The therapeutic efficacy of an exceedingly low dose of inhaled 1212C2 supports the rationale for local lung delivery for dose-sparing benefits, as compared to the conventional parenteral route of administration. These results suggest that the clinical development of 1212C2 formulated and delivered via inhalation for the treatment of SARS-CoV-2 infection should be considered. Twit Text FOAVip Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters ????Cell Rep Med http://www.kidney.de/pget.php?&tw=1&pmid=33649747 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33649747 #FOAvip English Wikipedia <ref>{{Cite pmid|33649747}}</ref> Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters #MMPMID33649747 Piepenbrink MS; Park JG; Oladunni FS; Deshpande A; Basu M; Sarkar S; Loos A; Woo J; Lovalenti P; Sloan D; Ye C; Chiem K; Bates CW; Burch RE; Erdmann NB; Goepfert PA; Truong VL; Walter MR; Martinez-Sobrido L; Kobie JJ Cell Rep Med 2021[Mar]; 2 (3): 100218 PMID33649747show ga SARS-CoV-2 infection results in viral burden in the respiratory tract, enabling transmission and leading to substantial lung pathology. The 1212C2 fully human monoclonal antibody was derived from an IgM memory B cell of a COVID-19 patient, has high affinity for the Spike protein receptor binding domain, neutralizes SARS-CoV-2, and exhibits in vivo prophylactic and therapeutic activity in hamsters when delivered intraperitoneally, reducing upper and lower respiratory viral burden and lung pathology. Inhalation of nebulized 1212C2 at levels as low as 0.6 mg/kg, corresponding to 0.03 mg/kg lung-deposited dose, reduced the viral burden below the detection limit and mitigated lung pathology. The therapeutic efficacy of an exceedingly low dose of inhaled 1212C2 supports the rationale for local lung delivery for dose-sparing benefits, as compared to the conventional parenteral route of administration. These results suggest that the clinical development of 1212C2 formulated and delivered via inhalation for the treatment of SARS-CoV-2 infection should be considered. |*COVID-19 Drug Treatment[MESH] |Administration, Inhalation[MESH] |Animals[MESH] |Antibodies, Monoclonal/classification/immunology/*therapeutic use[MESH] |COVID-19/virology[MESH] |Cricetinae[MESH] |Disease Models, Animal[MESH] |Epitope Mapping[MESH] |Epitopes/immunology[MESH] |Female[MESH] |Humans[MESH] |Immunoglobulin M/immunology[MESH] |Male[MESH] |Memory B Cells/cytology/metabolism[MESH] |Middle Aged[MESH] |Neutralization Tests[MESH] |Phylogeny[MESH] |Protein Domains/immunology[MESH] |SARS-CoV-2/immunology/isolation & purification[MESH]Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing huma(epmc).pdf DeepDyve Pubget Overpricing